4//SEC Filing
Esperion Therapeutics, Inc. 4
Accession 0000950142-15-000894
$ESPRCIK 0001434868operating
Filed
Apr 26, 8:00 PM ET
Accepted
Apr 27, 6:33 PM ET
Size
16.7 KB
Accession
0000950142-15-000894
Insider Transaction Report
Form 4
Purcell Dennis J
10% Owner
Transactions
- Sale
Common Stock
2015-04-24$106.10/sh−61,726$6,549,129→ 1,837,125 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-24$108.00/sh−5,743$620,244→ 1,898,851 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-23$109.10/sh−150,000$16,365,000→ 1,904,594 total(indirect: By Aisling Capital II, L.P.)
AISLING CAPITAL PARTNERS, LP
10% Owner
Transactions
- Sale
Common Stock
2015-04-24$108.00/sh−5,743$620,244→ 1,898,851 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-23$109.10/sh−150,000$16,365,000→ 1,904,594 total(indirect: By Aisling Capital II, L.P.) - Sale
Common Stock
2015-04-24$106.10/sh−61,726$6,549,129→ 1,837,125 total(indirect: By Aisling Capital II, LP)
AISLING CAPITAL PARTNERS LLC
10% Owner
Transactions
- Sale
Common Stock
2015-04-23$109.10/sh−150,000$16,365,000→ 1,904,594 total(indirect: By Aisling Capital II, L.P.) - Sale
Common Stock
2015-04-24$106.10/sh−61,726$6,549,129→ 1,837,125 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-24$108.00/sh−5,743$620,244→ 1,898,851 total(indirect: By Aisling Capital II, LP)
SCHIFF ANDREW N
10% Owner
Transactions
- Sale
Common Stock
2015-04-23$109.10/sh−150,000$16,365,000→ 1,904,594 total(indirect: By Aisling Capital II, L.P.) - Sale
Common Stock
2015-04-24$108.00/sh−5,743$620,244→ 1,898,851 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-24$106.10/sh−61,726$6,549,129→ 1,837,125 total(indirect: By Aisling Capital II, LP)
Aisling Capital II LP
10% Owner
Transactions
- Sale
Common Stock
2015-04-24$108.00/sh−5,743$620,244→ 1,898,851 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-24$106.10/sh−61,726$6,549,129→ 1,837,125 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-23$109.10/sh−150,000$16,365,000→ 1,904,594 total(indirect: By Aisling Capital II, L.P.)
ELMS STEVE
10% Owner
Transactions
- Sale
Common Stock
2015-04-23$109.10/sh−150,000$16,365,000→ 1,904,594 total(indirect: By Aisling Capital II, L.P.) - Sale
Common Stock
2015-04-24$108.00/sh−5,743$620,244→ 1,898,851 total(indirect: By Aisling Capital II, LP) - Sale
Common Stock
2015-04-24$106.10/sh−61,726$6,549,129→ 1,837,125 total(indirect: By Aisling Capital II, LP)
Footnotes (1)
- [F1]The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members of Aisling Partners. The individual managing members (collectively, the "Managers") of Aisling Partners are Dennis Purcell, Dr. Andrew Schiff and Steve Elms. Aisling GP, Aisling Partners, and the Managers share voting and dispositive power over the shares directly held by Aisling.
Documents
Issuer
Esperion Therapeutics, Inc.
CIK 0001434868
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001434868
Filing Metadata
- Form type
- 4
- Filed
- Apr 26, 8:00 PM ET
- Accepted
- Apr 27, 6:33 PM ET
- Size
- 16.7 KB